The purpose of this study was to perform a functional component analysis to optimize the recipes for Korean beef main bone area. To optimize the recipes for beef leg bone broth, beef feet broth and tail broth, the quality and physiochemical properties of the dishes were comparatived and investigated. Crude protein, crude fat and moisture showed significant differences among the beef leg bone broth, Beef feet broth and tail broth (p<0.001). All free amino acids showed significant differences, with the exception of cystine and tryptophan (p<0.05). All minerals showed significant differences (p<0.01). Na content was highest in the beef leg bone broth (211.77 mg/kg), followed by beef feet broth (254.40 mg/kg), and tail broth (134.93 mg/kg). Collagen was significantly different each dish (p<0.001), but chondroitin sulfate was not. And all nucleic acids showed significant differences.

콜라겐 함유량이 높은 한식메뉴에 대한 미생물학적 위해 평가를 위해 S. aureus와 Salmonella를 삼계탕, 어글탕, 오돌뼈 볶음, 전약, 족발에 접종하여 다양한 저장온도에서 세균수를 관찰하였다. 4oC의 저장온도에서는 5가지 콜라겐 함유식품에서 세균의 성장이 관찰되지 않았고, 10oC의 경우 삼계탕과 족발이 다른 식품에 비해 세균이 생장하는 패턴을 나타냈다. 저장온도 20oC에서는 전약을 제외한 나 머지 식품에서 세균이 생장하였고, 30oC에서도 전약만 세균수가 감소하는 것으로 관찰되었다. 5가지 콜라겐 함유 식품 중 전약만 고온 저장온도에서 위해세균의 활성이 관찰되지 않고 감소하는 경향을 나타냈기 때문에 전약에 첨 가된 정향, 대추, 계피, 생강, 후추에 대한 항균활성을 실험하였다. 그 결과 정향, 계피, 후추, 생강이 S. aureus에 대해 항균성을 보였고, Salmonella에 대해서는 정향과 계피만 항균력이 나타났으며, 대추는 항균능력이 없는 것으로 나타났다.

Patients with type II diabetes mellitus are more susceptible to colorectal cancer (CRC) incidence than non-diabetics. The anti-diabetic drug metformin is most commonly prescribed for the treatment of this disease and has recently shown antitumor effect in preclinical studies. The aberrant mutational activation in the components of RAS/RAF/MEK/ERK and PI3K/AKT/mTOR signaling pathway is very frequently observed in CRC. We previously reported that metformin inhibits the phosphorylation of ERK and BEZ235, a dual inhibitor of PI3K and mTOR, has anti-tumor activity against HCT15 CRC cells harboring mutations of KRAS and PIK3CA. Therefore, we hypothesized that simultaneous inhibition of two pathways by combining metformin with BEZ235 could be more effective in the suppression of proliferation than single agent treatment in HCT15 CRC cells. Here, we investigated the combinatory effect of metformin and BEZ235 on the cell survival in HCT15 CRC cells. Our study shows that both of the two signaling pathways can be blocked by this combinational strategy: metformin suppressed both pathways by inhibiting the phosphorylation of ERK, 4E-BP1 and S6, and BEZ235 suppressed PI3K/AKT/ mTOR pathway by reducing the phosphorylation of 4E-BP1 and S6. This combination treatment synergistically reduced cell viability. The combination index (CI) values ranged from 0.44 to 0.88, indicating synergism for the combination. These results offer a preclinical rationale for the potential therapeutic option for the treatment of CRC.